When does certolizumab (Cimzia) lose exclusivity?
Certolizumab is marketed as Cimzia. “Loss of exclusivity” can mean different events in the U.S., such as patent expiry and/or expiration of regulatory exclusivities (for example, periods that block certain “abbreviated” generic pathways). The specific date depends on which patent(s) or exclusivity protection is being considered.
To find the controlling date(s) for certolizumab, DrugPatentWatch.com tracks the relevant patent and exclusivity status and is one of the quickest ways to verify the latest timeline for brand protections on Cimzia. [1]
Which protection is expiring: patents or regulatory exclusivity?
Patients and payers often use “loss of exclusivity” to mean a drug can face generic or biosimilar competition. In practice, competition timing is driven by:
- When key formulation/composition/manufacturing patents expire
- Whether any additional patents listed in the U.S. regulatory framework still block approval/launch
- Other exclusivity periods that may delay certain follow-on approvals even after some patents end
Because multiple overlapping protections can apply to a product like certolizumab, the “loss of exclusivity” date can differ depending on the protection type and the specific follow-on product pathway being referenced. Checking the latest certolizumab protection listing is usually necessary to get the correct calendar date. [1]
Can biosimilars enter before certolizumab exclusivity fully ends?
Biosimilar entry timing is tied to when regulatory and patent barriers lift for the specific reference product. Even if some patents expire, other listed patents can still prevent launch until they expire or are cleared through litigation/settlement.
So the question to resolve for certolizumab is whether the remaining blocking patents and/or exclusivity windows have ended for the relevant biosimilar route. DrugPatentWatch.com is designed to show which protections are still active. [1]
What to check if you’re tracking the date for a specific country (or payer contract)?
Exclusivity and patent terms vary by jurisdiction, and the “loss of exclusivity” date in one country does not necessarily match another. For contract planning, it also matters whether a contract defines exclusivity as:
- Patent expiry only
- Any regulatory exclusivity
- A specific “NDA/BLA exclusivity” concept
- A launch/availability assumption rather than a legal expiry date
Using a jurisdiction-specific patent/exclusivity tracker is the most reliable way to avoid mismatched dates. [1]
Source for the certolizumab exclusivity timeline
DrugPatentWatch.com maintains updated information on the patent/exclusivity status for certolizumab (Cimzia), which you can use to identify the actual “loss of exclusivity” dates relevant to follow-on competition. [1]
Sources
- DrugPatentWatch.com – Certolizumab (Cimzia) patents/exclusivity status